1,721,294 research outputs found
Clinico-pathologic analysis of IGAP loci.
No full text<p>*Lambert et al., 2013 <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1004606#pgen.1004606-Lambert1" target="_blank">[11]</a>.</p><p>IGAP: International Genomics of Alzheimer's Project.</p><p>Bolded OR indicates an OR more extreme than that reported by the IGAP paper <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1004606#pgen.1004606-Lambert1" target="_blank">[11]</a>.</p><p>Bolded p-value indicates a p-value significant at the alpha = 0.05 level, uncorrected.</p><p>Clinico-pathologic analysis of IGAP loci.</p
eQTLs of IGAP GWAS SNPs in control brains (UKBEC).
No full texteQTLs of IGAP GWAS SNPs in control brains (UKBEC).</p
Recommended from our members
Translating Alzheimer's disease–associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs
No full textThe International Genomics of Alzheimer's Project (IGAP) is a consortium for characterizing the genetic landscape of Alzheimer's disease (AD). The identified and/or confirmed 19 single-nucleotide polymorphisms (SNPs) associated with AD are located on non-coding DNA regions, and their functional impacts on AD are as yet poorly understood. We evaluated the roles of the IGAP SNPs by integrating data from many resources, based on whether the IGAP SNP was (1) a proxy for a coding SNP or (2) associated with altered mRNA transcript levels. For (1), we confirmed that 12 AD-associated coding common SNPs and five nonsynonymous rare variants are in linkage disequilibrium with the IGAP SNPs. For (2), the IGAP SNPs in CELF1 and MS4A6A were associated with expression of their neighboring genes, MYBPC3 and MS4A6A, respectively, in blood. The IGAP SNP in DSG2 was an expression quantitative trait loci (eQTL) for DLGAP1 and NETO1 in the human frontal cortex. The IGAP SNPs in ABCA7, CD2AP, and CD33 each acted as eQTL for AD-associated genes in brain. Our approach for identifying proxies and examining eQTL highlighted potentially impactful, novel gene regulatory phenomena pertinent to the AD phenotype
Inferior gluteal artery perforator (IGAP) flap in autologous breast reconstruction: A proportional meta-analysis of surgical outcomes
No full textBackground: The inferior gluteal artery perforator (IGAP) flap is an alternative technique for autologous breast reconstruction. In contrast to other commonly used techniques, there is a paucity of literature on the safety and efficacy of the IGAP flap. The aim of this study was to perform a systematic literature review and meta-analysis of postoperative outcomes and complications associated with the IGAP in autologous breast reconstructions to validate its safety.
Methods: A systematic review of literature was performed following PRISMA guidelines. Articles reporting post-operative outcomes of IGAP flaps in autologous breast reconstruction were included. A proportional meta-analysis of post-operative complications was performed to obtain their proportions with 95% confidence intervals (CIs).
Results: Seven studies met the inclusion criteria, which represented a total of 239 IGAP flaps in 181 patients The total flap loss rate was 3% (95% CI 0-8%), partial flap loss rate was 2% (95% CI 0-4%), haematoma rate was 3% (95% CI 0-7%), overall donor-site complication rate was 15% (95% CI 5-28%), overall recipient-site complication rate was 24% (95% CI 15-34%), and the overall complication rate was 40% (95% CI 23-58%).
Conclusions: This meta-analysis provides comprehensive knowledge on the safety and efficacy of the IGAP flap in autologous breast reconstruction. It evidences the IGAP flap in autologous breast reconstruction's overall safety and validates its role as an effective option in breast reconstruction.</p
Expression of IGAP GWAS loci is associated with disease status in GSE5281.
No full textExpression of IGAP GWAS loci is associated with disease status in GSE5281.</p
The Intersectoral Global Action Plan (IGAP): A unique opportunity for neurology across the globe.
No full textThe World Health Assembly (WHA) approved the Intersectoral Global Action Plan (IGAP) in 2022. This ambitious project, formally called the Intersectoral Global Action Plan for Epilepsy and Other Neurological Disorders, is a 10-year plan to enhance neurology implementation worldwide and to raise the status of brain health and neurology services for patients with neurological diseases. The IGAP has 5 important components: relation with policy makers, therapy, prophylaxis, research, and public health. The implementation of IGAP is a challenge, not only for the specialty of neurology but for the whole neurological community, encompassing patients, carers, healthcare providers, and the public. The lack of a unified definition of neurology and the great variety of health systems, as well as the dependency on socioeconomic status, will necessitate custom-made solutions in all regions
O1‐09‐04: International Genomics of Alzheimer's Disease Project (IGAP) genome‐wide association study
No full text- …
